Comparable stake leader
GILEAD SCIENCES, INC.
SEC ownership of Arcus Biosciences, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001724521.
Disclosed value leader
GILEAD SCIENCES, INC.
Comparable rows
50/50
Latest evidence
30 Jun 2026
- Public ticker
- RCUS on NYSE
- Parsed ownership sources
-
13F, 13D/G, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
GILEAD SCIENCES, INC.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
GILEAD SCIENCES, INC.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001724521
- Issuer location
- Hayward, CA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Arcus Biosciences, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
GILEAD SCIENCES, INC.
Disclosed value leader
GILEAD SCIENCES, INC.
Comparable rows
50/50
Latest evidence
30 Jun 2026
13F
13D/G
3/4/5
Lead comparable stake: 25%
13D/G row: GILEAD SCIENCES, INC.
Showing 1-8 of 50 holder rows.
Quick read
GILEAD SCIENCES, INC. leads the comparable SEC ownership view at 25%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens GILEAD SCIENCES, INC.'s linked filing trail.
Comparable ownership
Top 5
GILEAD SCIENCES, INC.
25%
BlackRock, Inc.
10%
Point72 Asset Management, L.P.
4.1%
Carolyn C. Tang
0.15%
STATE STREET CORP
4.7%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| GILEAD SCIENCES, INC. |
13F
13D/G
3/4/5
Company · 10%+ Owner
|
25%
from 13D/G
|
$968,825,351
31,424,760 shares
|
— | 30 Jun 2026 |
| BlackRock, Inc. |
13F
13D/G
Company
|
10%
from 13D/G
|
$506,112,958
16,416,249 shares
|
— | 30 Jun 2026 |
| Point72 Asset Management, L.P. |
13D/G
|
4.1%
|
$58,921,714
4,332,479 shares
|
-$20,381,232 | 30 Sep 2025 |
| Carolyn C. Tang |
3/4/5
General Counsel
|
0.15%
|
$3,987,511
184,607 shares
|
-$318,496 | 11 Jun 2026 |
| STATE STREET CORP |
13F
Company
|
4.7%
|
$185,888,992
6,029,484 shares
|
— | 30 Jun 2026 |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
Company
|
4.6%
|
$181,756,661
5,895,448 shares
|
— | 30 Jun 2026 |
| MONTANOVA CAPITAL, LLC |
13F
Company
|
3.8%
|
$147,257,121
4,776,423 shares
|
— | 30 Jun 2026 |
| VANGUARD PORTFOLIO MANAGEMENT LLC |
13F
Company
|
3.5%
|
$137,980,528
4,475,528 shares
|
— | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$14,430,288.
Buys
$0
Insiders: 0
Sells
$14,430,288
Insiders: 7
Net
-$14,430,288
Shares: -645,205
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 645,205
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 105,389 | $0 | $3,060,254 | -$3,060,254 |
| 3-6 | 0 | 7,763 | $0 | $198,966 | -$198,966 |
| 6-9 | 0 | 270,887 | $0 | $6,200,038 | -$6,200,038 |
| 9-12 | 0 | 261,166 | $0 | $4,971,031 | -$4,971,031 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 20 reporting-owner rows connected to Arcus Biosciences, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
20
Largest Forms 3/4/5 holder
GILEAD SCIENCES, INC.
Net 12M change
-$14,430,287
Latest report
21 Aug 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| GILEAD SCIENCES, INC. | 10%+ Owner | $345,672,360 | Filing P/S | 18 Feb 2025 | ||
| Terry J. Rosen | Chief Executive Officer, Director | $53,293,626 | -$1,203,959 | -2.2% | Mixed | 23 Jan 2026 |
| Juan C. Jaen | President | $35,834,024 | -$9,219,222 | -20% | Mixed | 09 Jul 2026 |
| Yasunori Kaneko | Director | $20,691,827 | Mixed | 11 Jun 2026 | ||
| Jennifer Jarrett | Chief Operating Officer | $5,437,414 | -$2,171,347 | -29% | Mixed | 23 Jan 2026 |
| Carolyn C. Tang | General Counsel | $3,987,511 | -$318,496 | -7.4% | Mixed | 11 Jun 2026 |
| Kathryn E. Falberg | Director | $3,810,369 | Mixed | 11 Jun 2026 | ||
| II Robert C. Goeltz | Chief Financial Officer | $2,157,046 | -$855,891 | -28% | Filing P/S | 11 May 2026 |
| Richard Markus | Chief Medical Officer | $2,136,288 | -$210,144 | -9% | Mixed | 23 Jan 2026 |
| David L. Lacey | Director | $1,655,683 | Mixed | 11 Jun 2026 | ||
| Nuyten Dimitry SA | Chief Medical Officer | $1,407,289 | Mixed | 15 Dec 2024 | ||
| Alexander Azoy | Chief Accounting Officer | $1,187,430 | -$451,228 | -28% | Filing P/S | 21 Aug 2026 |
| Antoni Ribas | Director | $1,141,624 | Mixed | 11 Jun 2026 | ||
| Andrew J. Perlman | Director | $1,043,820 | Mixed | 11 Jun 2026 | ||
| Patrick Machado | Director | $956,880 | Mixed | 11 Jun 2026 | ||
| Nicole Lambert | Director | $928,800 | Mixed | 11 Jun 2026 | ||
| William Grossman | Chief Medical Officer | $414,460 | Mixed | 16 Jun 2021 | ||
| Dietmar Berger | Director | $0 | Mixed | 06 Feb 2025 | ||
| Johanna Mercier | Director | $0 | Mixed | 29 Jan 2024 | ||
| Linda Slanec Higgins | Director | Mixed | 10 Aug 2021 |
Recent insider transactions for Arcus Biosciences, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Alexander Azoy | RCUS | Common Stock | Sale | -6.67% | $84,810 | $30.00 | -2,827 | 39,581 | 21 Aug 2026 | Direct |
| Alexander Azoy | RCUS | Common Stock | Options Exercise | 7.14% | 2,827 | 42,408 | 21 Aug 2026 | Direct | ||
| Alexander Azoy | RCUS | Stock Option (right to buy) | Options Exercise | -47.9% | -2,827 | 3,073 | 21 Aug 2026 | Direct | ||
| Juan C. Jaen | RCUS | Common Stock | Sale | -2.38% | $574,288 | $28.62 | -20,067 | 822,240 | 10 Jul 2026 | By Trust |
| Juan C. Jaen | RCUS | Common Stock | Sale | -5.44% | $1,457,631 | $30.05 | -48,502 | 842,307 | 09 Jul 2026 | By Trust |
| Juan C. Jaen | RCUS | Common Stock | Sale | -0.72% | $190,740 | $29.66 | -6,431 | 890,809 | 24 Jun 2026 | By Trust |
| Juan C. Jaen | RCUS | Common Stock | Sale | -1.73% | $437,100 | $27.73 | -15,764 | 897,240 | 23 Jun 2026 | By Trust |
| Juan C. Jaen | RCUS | Common Stock | Sale | -1% | $249,661 | $27.03 | -9,236 | 913,004 | 22 Jun 2026 | By Trust |
| Nicole Lambert | RCUS | Common Stock | Award | 15.3% | 5,700 | 43,000 | 11 Jun 2026 | Direct | ||
| Nicole Lambert | RCUS | Stock Option (Right to Buy) | Award | 16,900 | 16,900 | 11 Jun 2026 | Direct | |||
| Patrick Machado | RCUS | Common Stock | Award | 14.8% | 5,700 | 44,300 | 11 Jun 2026 | Direct | ||
| Patrick Machado | RCUS | Stock Option (Right to Buy) | Award | 16,900 | 16,900 | 11 Jun 2026 | Direct | |||
| Yasunori Kaneko | RCUS | Common Stock | Award | 28.5% | 5,700 | 25,700 | 11 Jun 2026 | Direct | ||
| Yasunori Kaneko | RCUS | Stock Option (Right to Buy) | Award | 16,900 | 16,900 | 11 Jun 2026 | Direct | |||
| Carolyn C. Tang | RCUS | Common Stock | Options Exercise | 22.6% | 34,090 | 184,607 | 11 Jun 2026 | Direct | ||
| Carolyn C. Tang | RCUS | Stock Option (Right to Buy) | Options Exercise | -100% | -34,090 | 0 | 11 Jun 2026 | Direct | ||
| David L. Lacey | RCUS | Common Stock | Award | 8.03% | 5,700 | 76,652 | 11 Jun 2026 | Direct | ||
| David L. Lacey | RCUS | Stock Option (Right to Buy) | Award | 16,900 | 16,900 | 11 Jun 2026 | Direct | |||
| Kathryn E. Falberg | RCUS | Common Stock | Award | 14.8% | 5,700 | 44,300 | 11 Jun 2026 | Direct | ||
| Kathryn E. Falberg | RCUS | Stock Option (Right to Buy) | Award | 16,900 | 16,900 | 11 Jun 2026 | Direct | |||
| Antoni Ribas | RCUS | Common Stock | Award | 14.8% | 5,700 | 44,300 | 11 Jun 2026 | Direct | ||
| Antoni Ribas | RCUS | Stock Option (Right to Buy) | Award | 16,900 | 16,900 | 11 Jun 2026 | Direct | |||
| Andrew J. Perlman | RCUS | Common Stock | Award | 13.4% | 5,700 | 48,325 | 11 Jun 2026 | Direct | ||
| Andrew J. Perlman | RCUS | Stock Option (Right to Buy) | Award | 16,900 | 16,900 | 11 Jun 2026 | Direct | |||
| Alexander Azoy | RCUS | Common Stock | Sale | -6.08% | $66,024 | $25.77 | -2,562 | 39,581 | 01 Jun 2026 | Direct |
| II Robert C. Goeltz | RCUS | Common Stock | Sale | -8.45% | $198,966 | $25.63 | -7,763 | 84,161 | 11 May 2026 | Direct |
| Richard Markus | RCUS | Common Stock | Award | 36.6% | 24,000 | 89,647 | 23 Jan 2026 | Direct | ||
| Richard Markus | RCUS | Stock Option (right to buy) | Award | 96,000 | 96,000 | 23 Jan 2026 | Direct | |||
| Carolyn C. Tang | RCUS | Common Stock | Award | 19.2% | 24,000 | 148,734 | 23 Jan 2026 | Direct | ||
| Carolyn C. Tang | RCUS | Stock Option (right to buy) | Award | 96,000 | 96,000 | 23 Jan 2026 | Direct | |||
| Alexander Azoy | RCUS | Common Stock | Award | 113.6% | 21,050 | 39,581 | 23 Jan 2026 | Direct | ||
| Alexander Azoy | RCUS | Stock Option (right to buy) | Award | 14,050 | 14,050 | 23 Jan 2026 | Direct | |||
| Jennifer Jarrett | RCUS | Common Stock | Award | 16.1% | 31,000 | 224,024 | 23 Jan 2026 | Direct | ||
| Jennifer Jarrett | RCUS | Stock Option (right to buy) | Award | 126,000 | 126,000 | 23 Jan 2026 | Direct | |||
| II Robert C. Goeltz | RCUS | Common Stock | Award | 35.3% | 24,000 | 91,924 | 23 Jan 2026 | Direct | ||
| II Robert C. Goeltz | RCUS | Stock Option (right to buy) | Award | 96,000 | 96,000 | 23 Jan 2026 | Direct | |||
| Juan C. Jaen | RCUS | Common Stock | Award | 8.96% | 31,000 | 377,012 | 23 Jan 2026 | Direct | ||
| Juan C. Jaen | RCUS | Stock Option (right to buy) | Award | 126,000 | 126,000 | 23 Jan 2026 | Direct | |||
| Terry J. Rosen | RCUS | Common Stock | Award | 3.66% | 79,000 | 2,236,409 | 23 Jan 2026 | Direct | ||
| Terry J. Rosen | RCUS | Stock Option (right to buy) | Award | 315,000 | 315,000 | 23 Jan 2026 | Direct | |||
| Terry J. Rosen | RCUS | Common Stock | Gift | -1.6% | -35,000 | 2,157,409 | 08 Jan 2026 | Direct | ||
| Juan C. Jaen | RCUS | Common Stock | Sale | -3.34% | $681,342 | $21.41 | -31,823 | 922,240 | 05 Jan 2026 | By Trust |
| II Robert C. Goeltz | RCUS | Common Stock | Sale | -8.8% | $153,186 | $23.38 | -6,552 | 67,924 | 31 Dec 2025 | Direct |
| Terry J. Rosen | RCUS | Common Stock | Gift | -0.11% | -2,400 | 2,192,409 | 30 Dec 2025 | Direct | ||
| Alexander Azoy | RCUS | Common Stock | Sale | -19% | $96,614 | $22.25 | -4,343 | 18,531 | 18 Dec 2025 | Direct |
| Carolyn C. Tang | RCUS | Common Stock | Sale | -5.18% | $150,906 | $22.16 | -6,810 | 124,734 | 17 Dec 2025 | Direct |
| Richard Markus | RCUS | Common Stock | Sale | -6.41% | $99,585 | $22.16 | -4,494 | 65,647 | 17 Dec 2025 | Direct |
| Alexander Azoy | RCUS | Common Stock | Sale | -8.46% | $46,823 | $22.16 | -2,113 | 22,874 | 17 Dec 2025 | Direct |
| II Robert C. Goeltz | RCUS | Common Stock | Sale | -7.41% | $132,071 | $22.16 | -5,960 | 74,476 | 17 Dec 2025 | Direct |
| Jennifer Jarrett | RCUS | Common Stock | Sale | -4.92% | $221,218 | $22.16 | -9,983 | 193,024 | 17 Dec 2025 | Direct |
* marks a reported price that did not pass the local price check.